Cytosorbents financials
$4.00−0.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M | $41.0M | $24.9M | $22.5M | $15.2M | $9.5M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M | $30.0M | $17.6M | $15.0M | $9.6M | $5.6M |
| Gross margin | 71.5% | 69.9% | 70.6% | 59.8% | 74.4% | 73.0% | 70.5% | 66.7% | 63.6% | 58.5% |
| Operating income | -$14.7M | -$16.5M | -$31.9M | -$31.5M | -$22.7M | -$10.4M | -$19.0M | -$15.6M | -$9.8M | -$11.5M |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M | -$24.6M | -$7.8M | -$19.3M | -$17.2M | -$8.8M | -$11.8M |
| Net margin | −22.1% | −58.2% | −94.1% | −94.6% | −56.9% | −19.1% | −77.2% | −76.5% | −58.1% | −123.5% |
| Diluted EPS | $-2.60 | $-7.60 | $-13.00 | $-15.00 | $-11.40 | $-4.00 | $-12.00 | $-11.20 | $-6.40 | $-9.20 |
| EBITDA | -$12.7M | -$14.9M | -$30.5M | -$30.6M | -$22.0M | -$9.7M | -$18.4M | -$15.2M | -$9.6M | -$11.3M |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M | -$14.0M | -$5.6M | -$16.8M | -$10.8M | -$6.5M | -$6.7M |
| Free cash flow | -$12.5M | -$14.7M | -$22.2M | -$34.3M | -$17.6M | -$6.3M | -$17.5M | -$11.5M | -$7.5M | -$6.9M |
| Diluted shares | 3.1M | 2.7M | 2.2M | 2.2M | 2.2M | 1.9M | 1.6M | 1.5M | 1.4M | 1.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.2M | $3.3M | $14.1M | $22.1M | $52.1M | $71.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $16.7M | $14.0M | $5.0M | $5.0M | $0.00 | $0.00 |
| Total assets | $44.2M | $47.4M | $53.0M | $63.2M | $89.5M | $90.0M |
| Total liabilities | $38.3M | $36.3M | $29.5M | $27.9M | $26.9M | $10.7M |
| Shareholders' equity | $5.9M | $11.1M | $23.5M | $35.4M | $62.6M | $79.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology